Project Description


In January 2018, the TB CARE II team held a two-day meeting on the Drug-Resistant TB Phase III Trial Results. The meeting fostered collaborative discussions about the results and questions raised by TB programs, partners, technical assistance organizations, patients, advocates, and clinical providers on the results from Stage 1 of the STREAM Trial and Delamanid Trial 213. The meeting provided stakeholders to share their perspective on how to best utilize results from these trials to advance improved management of DR-TB and form future policy and research agendas.